Background-Low activity of the sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2a) resulting from strong inhibition by phospholamban (PLN) can depress cardiac contractility and lead to dilated cardiomyopathy and heart failure. Here, we investigated whether PLN exhibits cardiotoxic effects via mechanisms other than chronic inhibition of SERCA2a by studying a PLN mutant, PLN R9C , that triggers cardiac failure in humans and mice. Methods and Results-Because PLN R9C inhibits SERCA2a mainly by preventing deactivation of wild-type PLN, SERCA2a activity could be increased stepwise by generating mice that carry a PLN R9C transgene and 2, 1, or 0 endogenous PLN alleles (PLN ϩ/ϩ ϩTgPLN R9C , PLN ϩ/Ϫ ϩTgPLN R9C , and PLN Ϫ/Ϫ ϩTgPLN R9C , respectively). PLN Ϫ/Ϫ ϩTgPLN R9C hearts demonstrated accelerated sarcoplasmic reticulum Ca 2ϩ uptake rates and improved hemodynamics compared with PLN ϩ/ϩ ϩTgPLN R9C mice but still responded poorly to ␤-adrenergic stimulation because PLN R9C impairs protein kinase A-mediated phosphorylation of both wild-type and mutant PLN. PLN ϩ/ϩ ϩTgPLN R9C mice died of heart failure at 21Ϯ6 weeks, whereas heterozygous PLN ϩ/Ϫ ϩTgPLN R9C mice survived to 48Ϯ11 weeks, PLN Ϫ/Ϫ ϩTgPLN R9C mice to 66Ϯ19 weeks, and wild-type mice to 94Ϯ27 weeks (PϽ0.001). Although Ca 2ϩ reuptake kinetics in young PLN Ϫ/Ϫ ϩTgPLN R9C mice exceeded those measured in wild-type control animals, this parameter alone was not sufficient to prevent the eventual development of dilated cardiomyopathy. Conclusions-The data demonstrate an association between the dose-dependent inhibition of SERCA2a activity by PLN wt and the time of onset of heart failure and show that a weak inhibitor of SERCA2a, PLN R9C , which is diminished in its ability to modify the level of SERCA2a activity, leads to heart failure despite fast sarcoplasmic reticulum Ca 2ϩ reuptake. (Circulation. 2009;119:436-444.)
D ilated cardiomyopathy (DCM), characterized by left ventricular dilatation and systolic dysfunction, is a leading cause of cardiovascular morbidity and mortality. In Ϸ30% of all cases, direct relatives of affected individuals also show symptoms of DCM, suggesting a genetic origin of the disease. Most of the disease-causing mutations are located in genes that encode cytoskeletal proteins, but mutations in the sarcomere and nuclear lamin proteins also have been reported. Studies of genetically engineered animal models have identified defects in force transmission, endoplasmic reticulum stress response, apoptosis, and biomechanical stress as important players in the pathogenesis of DCM. [1] [2] [3] 
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Previously, we described a pathway leading to DCM, heart failure, and premature death that is caused by specific changes in myocyte Ca 2ϩ reuptake resulting from the heterozygous substitution of cysteine for arginine 9 (R9C) in phospholamban (PLN). 4 PLN is a small transmembrane protein located in the sarcoplasmic reticulum (SR) that regulates the activity of the sarco(endo)plasmic reticulum Ca 2ϩ -ATPase isoform 2a (SERCA2a). Ca 2ϩ transport into the SR by SERCA2a accounts for at least 70% of the removal of Ca 2ϩ from the cytosol during cardiac relaxation. PLN binds to SERCA2a and inhibits its activity by lowering its apparent affinity for Ca 2ϩ . As a result, PLN determines myocardial relaxation rates and influences cardiac contractility. 5 The inhibitory effect of PLN on SERCA2a is relieved on phosphorylation of PLN at serine 16 by protein kinase A (PKA). 6, 7 The PLN R9C mutant protein inhibits PKA-mediated PLN phosphorylation of both mutant (PLN R9C ) and wild-type (PLN wt ) PLN in heterozygous humans and mice, leading to a situation in which more PLN remains in its active inhibitory state, thereby reducing SR Ca 2ϩ uptake rates. 4 Depressed SR Ca 2ϩ cycling is commonly observed in failing human myocardia. 8 When mimicked in mouse models, for example, by overexpression of PLN, the contractile performance of the heart also is impaired. 9 By contrast, PLN-null mice have a nearly normal life span without overt cardiac problems. 10, 11 A partial or complete reduction in PLN inhibitory activity, which enhances SR Ca 2ϩ uptake and increases cardiac contractility, has been shown to rescue certain mouse models of heart failure. 10, 12, 13 These findings indicate that chronic inhibition or superinhibition of SERCA2a activity by mutant forms of PLN causes heart failure, whereas reduced PLN inhibitory activity may even prevent it. However, the identification of a human PLN L39stop mutation as a causal factor in recessively inherited DCM suggests that loss of PLN may be lethal in humans because the mutation led to a truncated form of PLN that was equivalent to a null allele. 14 This discrepancy between humans and mice can be rationalized by the differences in human and mouse cardiac physiology in that slow-beating human hearts may be more dependent on PLN inhibitory function than mouse hearts, the latter constantly operating close to their maximal heart rate. 14 A second possible explanation could be that parameters of PLN function other than high PLN inhibitory activity may contribute to the development of heart failure.
The goal of the present study was to further define the relations between PLN malfunction and the development of heart failure. The level of PLN inhibitory activity was decreased stepwise in transgenic mice expressing the PLN R9C mutation by ablation of 1 or both PLN wt alleles. We report here that the time of onset of lethal DCM depends on the gene dosage of the PLN wt gene and the rate of SR Ca 2ϩ uptake in hearts expressing PLN R9C . However, the PLN R9C defect is more complicated because detrimental remodeling processes were triggered, albeit at a later stage, in the absence of wild-type PLN and in the presence of enhanced Ca 2ϩ reuptake rates. Analyses in vitro and in vivo suggest that the inability to modulate the activity of the Ca 2ϩ -ATPase appropriately may provide an independent stimulus for the development of heart failure.
Methods
Mice expressing PLN R9C under the control of the cardiac ␣-myosin heavy chain promoter (PLN ϩ/ϩ ϩTgPLN R9C mice) 4 were crossed with PLN-ablated mice (PLN Ϫ/Ϫ mice; a generous gift from Dr Evangelia G. Kranias, Department of Pharmacology and Cell Biophysics, University of Cincinnati, Cincinnati, Ohio) 10 to generate transgenic mice that carry 1 (PLN ϩ/Ϫ ϩTgPLN R9C ) or 0 (PLN Ϫ/Ϫ ϩTgPLN R9C ) endogenous PLN alleles. Contractile properties of mouse hearts were investigated by in vivo left ventricular catheterization and echocar-diography. 15 Ca 2ϩ kinetics and sarcomere mechanics were measured in isolated myocytes. 16 Ca 2ϩ transport assays were carried out in microsomal preparations of transfected HEK-293 cells. 17 See the online-only Data Supplement for an expanded description.
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Results

Ablation of Endogenous PLN Prevents DCM and Heart Failure in PLN R9C Transgenic Mice
Mice overexpressing a PLN R9C transgene under the control of the cardiac ␣-myosin heavy chain promoter (PLN ϩ/ϩ ϩTgPLN R9C ) progressively developed DCM and terminal heart failure. 4 Twenty weeks after birth, these hearts showed massive dilatation of ventricular chambers and enlarged atria ( Figure 1A ). Cardiac histology was characterized by irregularly shaped nuclei, myocyte enlargement, and substantial interstitial collagen depositions. Lungs and livers of PLN ϩ/ϩ ϩTgPLN R9C mice were enlarged and dark red, and histology revealed signs of vascular congestion, indicating failure of the left and right ventricles ( Figure 1B) . In contrast, the size and histology of the heart, lungs, and liver were regular in PLN Ϫ/Ϫ ϩTgPLN R9C mice at 20 weeks of age ( Figure 1A and 1B).
Twenty-week-old PLN ϩ/ϩ ϩTgPLN R9C and PLN Ϫ/Ϫ ϩTgPLN R9C mice were further evaluated for hemodynamic function using left ventricular catheterization ( Figure 1C ). Rates of pressure change (dP/dtmax and dP/dtmin) and maximum left ventricular pressures were distinctly depressed in PLN ϩ/ϩ ϩTgPLN R9C hearts compared with wild-type hearts, indicating heart failure. However, the performance of PLN Ϫ/Ϫ ϩTgPLN R9C hearts closely resembled that of wild-type hearts. PLN Ϫ/Ϫ ϩTgPLN R9C hearts exhibited significantly higher rates of pressure change than PLN ϩ/ϩ ϩTgPLN R9C hearts. Heart rates were similar in all mouse lines.
Development of Left Ventricular Dilatation and Contractile Dysfunction Resulting From PLN R9C Depends on the Gene Dosage of PLN wt
We also analyzed mice bearing the PLN R9C transgene and only 1 PLN wt allele (PLN ϩ/Ϫ ϩTgPLN R9C ) to further investigate the relation between PLN wt gene dosage and the development of DCM and decreased cardiac contractile function. As analyzed by echocardiography of 26-week-old mice, fractional shortening was lower by 35% in PLN ϩ/ϩ ϩTgPLN R9C hearts (PϽ0.001), by 33% in PLN ϩ/Ϫ ϩTgPLN R9C hearts (PϽ0.001), and by 18% in PLN Ϫ/Ϫ ϩTgPLN R9C hearts (PϽ0.001) compared with wild-type mice ( Figure 2 ). Left ventricular endsystolic diameter had increased 3.4-fold in PLN ϩ/ϩ ϩTgPLN R9C (PϽ0.01), 2.8-fold in PLN ϩ/Ϫ ϩTgPLN R9C mice (PϽ0.001), and 1.9-fold in PLN Ϫ/Ϫ ϩTgPLN R9C mice (PϽ0.01). Apparently, all mouse lines bearing the PLN R9C transgene had developed contractile dysfunction and dilatation of left ventricles at 26 weeks of age, the extent correlating with the dosage of PLN wt . Fractional shortening was moderately decreased even in PLN Ϫ/Ϫ ϩTgPLN R9C compared with wild-type mice as a result of mild left ventricular dilatation. In no case was left ventricular wall thickness increased over wild-type values, indicating a direct progression to pure DCM (see also Reference 4) .
Protein levels of SERCA2a and other Ca 2ϩ handling proteins were shown to be equal in all mouse lines at 10 weeks of age. PLN R9C expression was estimated to be similar or slightly higher than PLN wt expression in PLN ϩ/ϩ ϩTgPLN R9C hearts ( Figure IA 
Enhanced SR Ca 2؉ Uptake Rates and Regular Myocyte Mechanics in PLN ؊/؊ ؉TgPLN R9C Mice
In view of decreased PLN wt phosphorylation in the presence of PLN R9C , which reduces SR Ca 2ϩ -ATPase activity, 4 we wondered whether the abnormal Ca 2ϩ kinetics of myocytes expressing PLN R9C were normalized when PLN wt was ablated. Therefore, SR Ca 2ϩ transients were measured in isolated ventricular myocytes taken from 8-to 10-week-old mice and electrically stimulated at 0.5 Hz ( Figure 3A ). In our experiments, the rate of SR Ca 2ϩ release (T 80% peak) and the amplitude of the Ca 2ϩ transient were not significantly different among PLN ϩ/ϩ ϩTgPLN R9C , PLN Ϫ/Ϫ , PLN Ϫ/Ϫ ϩTgPLN R9C , and wild-type cells. SR Ca 2ϩ contents were estimated from the amount of Ca 2ϩ release on application of 10 mmol/L caffeine. Measurements showed a trend but no significant difference for higher SR Ca 2ϩ loads in the absence of PLN wt . The return of Ca 2ϩ to the SR via SERCA2a (T 50% baseline and T 90% baseline) was slower in PLN ϩ/ϩ ϩTgPLN R9C cells than in wild-type cells (PϽ0.01). However, in PLN Ϫ/Ϫ myocytes, SR Ca 2ϩ uptake was accelerated in both the presence and absence of PLN R9C (PϽ0.01). Intriguingly, in PLN Ϫ/Ϫ ϩTgPLN R9C myocytes, Ca 2ϩ uptake rates were faster than in wild-type myocytes (PϽ0.01). We conclude that SR Ca 2ϩ uptake rates are slow in myocytes expressing PLN R9C only in the presence of PLN wt .
In parallel with measurements of SR Ca 2ϩ transients, the rates of contraction and relaxation were recorded with the edge detection method to investigate the mechanical consequences of altered Ca 2ϩ kinetics ( Figure 3B ). Cell length was similar in all groups. However, the PLN R9C transgene decelerated myocyte relaxation compared with wild-type myocytes (PϽ0.05), but in the absence of endogenous PLN (PLN Ϫ/Ϫ ϩTgPLN R9C ), myocyte relaxation was not significantly different from that of wild-type cells. Contractile speed was equal in wild-type and PLN ϩ/ϩ ϩTgPLN R9C myocytes but slightly faster in PLN Ϫ/Ϫ and PLN Ϫ/Ϫ ϩTgPLN R9C myocytes (PϽ0.01), presumably because of enhanced restocking of cellular Ca 2ϩ stores in the PLN-null background. The data show impaired relaxation rates of PLN R9C myocytes, which are rescued by ablation of PLN wt (PLN Ϫ/Ϫ ϩTgPLN R9C ).
Ca 2؉ Transport Rates of HEK-293 Cells Transfected With PLN R9C Depend on the Amount of Coexpressed PLN wt
Ca 2ϩ uptake rates also were measured in microsomal preparations from HEK-293 cells transfected with SERCA2a, PLN wt , and PLN R9C . These preparations permitted selective analysis of the inhibitory activities of PLN R9C and PLN wt in an unphosphorylated state. At various Ca 2ϩ concentrations Ͻ10 mol/L, the activity of SERCA2a was higher in cells expressing SERCA2a and PLN R9C than in cells expressing SERCA2a and PLN wt ( Figure 3C ). EC 50 values were 200Ϯ13 nmol/L for SERCA2a alone and 532Ϯ37 nmol/L for SERCA2aϩPLN wt but only 248Ϯ12 nmol/L for SERCA2aϩPLN R9C (PϽ0.001). Myocyte relaxation was faster in PLN Ϫ/Ϫ ϩTgPLN R9C than in PLN ϩ/ϩ ϩTgPLN R9C cells but did not exceed that measured in wild-type cells. C-E, HEK-293 cells were transfected with cDNA of SERCA2a, PLN wt , and/or PLN R9C , and rates of Ca 2ϩ uptake were measured in microsomal fractions. C, At different Ca 2ϩ concentrations, the Ca 2ϩ affinity of SERCA2a in cells transfected with PLN R9C was higher than in cells transfected with equivalent amounts of PLN wt and almost as high as in cells transfected with SERCA2a alone. D, Cotransfection of PLN wt and PLN R9C exhibited no dominant effect on PLN wt in this experimental setting (absence of PKA). E, EC 50 for Ca 2ϩ uptake via SERCA2a (in PCA units) measured in HEK-293 cells transfected with SERCA2a, PLN wt , and PLN R9C as indicated below the diagram (g). EC 50 values correlated with the amount of PLN wt . The profiles using mouse or human PLN protein were very similar. Values represent at least 3 independent experiments. T 80% peak indicates time to 80% peak height of the Ca 2ϩ signal; T 50% baseline, time to 50% decay of the Ca 2ϩ signal; T 90% baseline, time to 90% decay of the Ca 2ϩ signal; T 50% contraction, time to 50% myocyte shortening; and T 50% relaxation, time to 50% myocyte relengthening. *PϽ0.05 vs wild-type mice.
On cotransfection of equal amounts of PLN R9C and PLN wt cDNA, the Ca 2ϩ affinity of SERCA2a was almost equal to that found for cotransfection with PLN wt alone ( Figure 3D ). The results indicate that PLN R9C alone exhibits little inhibitory effect on SERCA2a or, in the absence of kinases, on PLN-dependent SERCA2a regulation.
Next, HEK-293 cells were transfected with SERCA2a and varying ratios of PLN wt and PLN R9C ( Figure 3E ). For expression of SERCA2a alone, the EC 50 for CA 2ϩ uptake was 6.7 pCa units but was reduced by 0.42 pCa units in the presence of PLN wt . In the presence of PLN R9C , EC 50 was 6.61, for a decrease of only 0.09 pCa units. If the ratio of PLN wt to PLN R9C was 2:6, EC 50 was reduced by 0.24 pCa units, and if the ratio of PLN wt to PLN R9C was 4:4, EC 50 was reduced by 0.387 pCa units. We conclude that the inhibitory effects of unphosphorylated PLN R9C and PLN wt are additive and depend largely on the amount of coexpressed PLN wt . By extrapolation, in the presence of equal amounts of PLN wt and PLN R9C , as occurs in heterozygous humans with DCM, PLN wt function is likely to predominate and, in an unphosphorylated state, would be almost as strong an inhibitor in the presence of an equal amount of PLN R9C as in its absence (inhibitory effect, Ϫ0.38 pCa units versus Ϫ0.42 pCa units in HEK-293 cells). As further illustrated in Figure 3E , relative loss of function resulting from the R9C mutation was equivalent in murine and human PLN, the latter carrying an asparagine instead of a lysine in position 27 and known to exhibit a stronger inhibitory effect on SERCA2a than PLN of other species. 18
Late-Onset DCM, Decreased Cardiac Contractile Function, and Death in PLN ؊/؊ ؉TgPLN R9C Mice
The fast Ca 2ϩ reuptake kinetics in the absence of PLN wt provided a molecular explanation for the improved heart phenotype of PLN Ϫ/Ϫ ϩTgPLN R9C mice. Intriguingly, at 60 weeks of age, all cardiac chambers of these mice were bigger than in age-matched wild-type hearts ( Figure 4A ). Histological sections revealed enlarged myocytes, nuclei with irregular size and shape, and interstitial fibrosis, indicating that although PLN R9C promotes DCM significantly via PLN wt , PLN R9C on its own also can trigger adverse cardiac remodeling processes.
The direct contribution of PLN R9C to the structural and functional decline was further analyzed by echocardiographic comparison of PLN Ϫ/Ϫ ϩTgPLN R9C and PLN Ϫ/Ϫ mice ( Figure  4B ). Fractional shortening of PLN Ϫ/Ϫ ϩTgPLN R9C hearts at 60 weeks of age was only 46% compared with 69% in PLN Ϫ/Ϫ hearts (Pϭ0.01). Left ventricular dimensions of PLN Ϫ/Ϫ ϩTgPLN R9C hearts were higher than in PLN Ϫ/Ϫ mice at both end diastole (34% higher; PϽ0.01) and end systole (135% higher; PϽ0.01). Compared with 26-week-old mice ( Figure  2) , left ventricular end-diastolic and end-systolic diameters of PLN Ϫ/Ϫ ϩTgPLN R9C hearts had increased by 13% (PϽ0.05) and 73% (PϽ0.01), respectively, and fractional shortening had declined by 29% (PϽ0.01), indicating the development of left ventricular dilatation and contractile dysfunction.
Invasive measurements of left ventricular hemodynamics demonstrated normal left ventricular maximal pressures in 1-year-old PLN Ϫ/Ϫ ϩTgPLN R9C mice ( Figure 4C ). However, rates of pressure rise and pressure fall (dP/dtmax and dP/ dtmin) were depressed compared with age-matched PLN Ϫ/Ϫ mice; differences in dP/dtmax and heart rate became significant only after administration of dobutamine (PϽ0.05). This depression of cardiac hemodynamics, along with a poor response to ␤-adrenergic stimulation, indicates that PLN Ϫ/Ϫ ϩTgPLN R9C hearts, but not PLN Ϫ/Ϫ hearts, are failing at 1 year of age.
PLN Ϫ/Ϫ ϩTgPLN R9C mice died at an average age of 66Ϯ17 weeks (averageϮSD) ( Figure 5 ). On autopsy, chests were filled with clear fluid, lungs were dark red, and hearts showed massive dilatation consistent with symptoms of terminal heart failure. PLN Ϫ/Ϫ ϩTgPLN R9C mice lived Ϸ3 times longer than PLN ϩ/ϩ ϩTgPLN R9C mice (23Ϯ6 weeks) but clearly shorter than wild-type FVB mice (94Ϯ27 weeks; PϽ0.001). Mice carrying the PLN R9C transgene and only 1 endogenous PLN allele (PLN ϩ/Ϫ ϩTgPLN R9C ) lived for 48Ϯ11 weeks. This was shorter than the mean life span of PLN Ϫ/Ϫ ϩTgPLN R9C mice but longer than that of PLN ϩ/ϩ ϩTgPLN R9C mice (PϽ0.001).
PLN ؊/؊ ؉TgPLN R9C Mice Do Not Respond to ␤-Adrenergic Stimulation
In the absence of PLN wt , PLN R9C still causes late-onset heart failure, despite fast Ca 2ϩ reuptake kinetics. Therefore, PLN R9C alone must damage the myocardium by mechanisms that are independent of PLN wt and independent of a high degree of SERCA2a inhibition. Because the R9C mutation inhibits PKA-mediated phosphorylation of serine 16, we further studied the physiological effects of ␤-adrenergic stimulation on PLN Ϫ/Ϫ ϩTgPLN R9C myocytes compared with wild-type cells (see Figure 3A and 3B for basal cardiomyocyte function). ␤-Adrenergic agonists normally lead to phosphorylation of PKA target proteins such as L-type Ca 2ϩ channels, RyR2, and PLN. Consequently, myocyte contraction and relaxation are accelerated by enhanced intracellular Ca 2ϩ kinetics. Ca 2ϩ transients of isolated myocytes were measured after addition of isoproterenol to the perfusion buffer compared with unstimulated cells. In our experiments, the increases on isoproterenol stimulation in both the amount (⌬amplitude [isoϪbasal]) and the rate (⌬T 80% peak [isoϪbasal]) of SR Ca 2ϩ release were not different in PLN Ϫ/Ϫ ϩTgPLN R9C and wild-type cells ( Figure 6A) . Notably, the speed of SR Ca 2ϩ reuptake was accelerated significantly in wild-type cells on adrenergic activation (decrease in T 90% baseline from 192Ϯ7 to 140Ϯ14 ms; PϽ0.01) and not in PLN Ϫ/Ϫ ϩTgPLN R9C myocytes (decrease in T 90% baseline from 130Ϯ6 to 126Ϯ6 ms; PϭNS).
Accordingly, isoproterenol was able to enhance myocyte relaxation rates, which depend largely on the level of PLN activity, in wild-type cells (PϽ0.01; Figure 6B ) but not in PLN Ϫ/Ϫ ϩTgPLN R9C myocytes (PϭNS). The amplitude and speed of myocyte contraction increased in all cells on isoproterenol stimulation. These results would most likely be due to the effects of PKA phosphorylation on L-type Ca 2ϩ channels or RyR2 and might reflect an increased size of the Ca 2ϩ store resulting from enhanced SERCA2a activity on stimulation. The amplitude and speed of myocyte contraction were not significantly different in wild-type and PLN Ϫ/Ϫ ϩTgPLN R9C myocytes, suggesting regular phosphorylation of Ca 2ϩ release channels.
The response to ␤-adrenergic stimulation was further evaluated in vivo by invasive left ventricular catheterization of 20-week-old PLN Ϫ/Ϫ ϩTgPLN R9C mice compared with wild-type mice ( Figure 6C ). At this age, PLN Ϫ/Ϫ ϩTgPLN R9C hearts showed no signs of heart failure at baseline (Figure 1 ). However, PLN Ϫ/Ϫ ϩTgPLN R9C hearts failed to accelerate the speed of pressure decay (dP/dtmin) during infusion of dobutamine (1.5 g/min): dP/dtmin fell by 24Ϯ10% in wild-type hearts (PϽ0.01) but only by 5Ϯ3% in PLN Ϫ/Ϫ ϩTgPLN R9C hearts (PϭNS). The limited acceleration of SR Ca 2ϩ uptake rates in PLN Ϫ/Ϫ ϩTgPLN R9C myocytes on stimulation with isoproterenol ( Figure 6A ) and the lack of a lusitropic effect in PLN Ϫ/Ϫ ϩTgPLN R9C myocytes and whole hearts ( Figure 6B and 6C) are explained by the resistance of PLN R9C to PKA-mediated phosphorylation and by the limited inhibitory effect of PLN R9C itself on the Ca 2ϩ -ATPase.
Discussion
We have shown previously that PLN R9C leads to DCM, heart failure, and premature death in heterozygous humans and transgenic mice (PLN ϩ/ϩ ϩTgPLN R9C ). 4 PLN R9C prevents phosphorylation of coexpressed PLN wt and thereby decelerates diastolic Ca 2ϩ transport into the SR via SERCA2a (Figure 3A) . Unlike the nearly normal inhibitory effect that is measured in transfected HEK-293 cells when PLN R9C is present together with PLN wt , SERCA2a inhibition by PLN R9C alone is weak ( Figure 3C and 3E) . Thus, cardiomyocyte expression of PLN R9C alone (PLN Ϫ/Ϫ ϩTgPLN R9C ) results in SR Ca 2ϩ uptake rates that are faster than those in wild-type myocytes and almost as fast as those in PLN Ϫ/Ϫ myocytes ( Figure 3A and 3C) . The acceleration of SR Ca 2ϩ reuptake kinetics as a result of PLN wt ablation was accompanied by an improved morphological and functional phenotype of the hearts (Figures 1 and 2) ; lower expression of atrial natriuretic peptide, brain natriuretic peptide, and ␤-myosin heavy chain ( Figure IC of the online-only Data Supplement); and a 3-fold-longer survival of PLN Ϫ/Ϫ ϩTgPLN R9C mice compared with PLN ϩ/ϩ ϩTgPLN R9C mice ( Figure 5 ). These data provide evidence that the dominant effect of PLN R9C on PLN wt plays an important role in the progression of heart failure when both forms are present. The pronounced benefit to the life span of PLN R9C transgenic animals that arises from ablation of PLN confirms that the ratio of SERCA2a to PLN activity is a promising target for the prevention of DCM and heart failure. PLN ablation and SERCA2a overexpression have been reported to improve the structural and/or functional phenotype in several experimental models of heart failure. Examples are mice lacking the muscle-specific LIM protein and mice with transgenic overexpression of the Ca 2ϩ storage protein calsequestrin or the ␤ 1 -adrenergic receptor. 12, 13, 19 On the other hand, PLN ablation had little or no effect on left ventricular dysfunction in myosin-binding protein C-deficient mice or in mice overexpressing the sarcomeric protein tropomodulin. 20, 21 In our mouse model, PLN ablation delayed both structural and functional signs of heart failure by several months and tripled the survival time, on average, from Ϸ21 weeks to Ϸ66 weeks, suggesting that PLN ablation is a highly efficient intervention for delaying the onset of heart failure that arise in full or in part from Ca 2ϩ dysregulation. Importantly, even a partial mending of the underlying Ca 2ϩ cycling defect, as in PLN R9C transgenic mice with only 1 PLN wt allele, largely improved the phenotype (Figure 5 ). PLN Ϫ/Ϫ ϩTgPLN R9C mice demonstrated faster Ca 2ϩ uptake rates than wild-type mice ( Figure 3A and 3C ). According to current theories, fast Ca 2ϩ reuptake does not lead to heart failure but may even prevent it. 12, 22 However, PLN Ϫ/Ϫ ϩTgPLN R9C mice progressively developed DCM during adulthood and eventually died of heart failure at 66Ϯ19 weeks of age (Figures 4 and 5 ). We conclude that the PLN R9C mutation promotes heart failure via at least 2 distinct mechanisms. One is chronic slow SR Ca 2ϩ uptake, which is crucial to heterozygous humans and PLN ϩ/ϩ ϩTgPLN R9C mice. A second pathway that causes heart failure in PLN Ϫ/Ϫ ϩTgPLN R9C mice is independent of SR Ca 2ϩ uptake rates. A mechanism that is independent from SERCA2a function cannot be ruled out but appears unlikely because PLN specifically interacts with SERCA2a and the phosphorylation defect induced by PLN R9C seems to be confined to PLN ( Figure IA , online-only Data Supplement).
In PLN Ϫ/Ϫ ϩTgPLN R9C mice, PLN R9C inhibits SR Ca 2ϩ reuptake less than PLN wt , but PLN R9C also blocks the capacity to alter the inhibitory activity of PLN wt and PLN R9C via PKA-mediated phosphorylation ( Figure 6 ). Consequently, cardiac relaxation, which largely determines diastolic filling and cardiac stroke volume, remains fixed at a certain rate. Therefore, we propose that the resulting inability of PLN Ϫ/Ϫ ϩTgPLN R9C hearts to adjust adequately to the changing requirements during low and high activity of the heart may act as an independent trigger for heart failure. As illustrated in our working model, diagrammed in Figure 7 , healthy myo- cytes alter Ca 2ϩ transport velocities into the SR by phosphorylation and dephosphorylation of PLN ( Figure 7A ). In contrast, this regulatory mechanism is impaired in myocytes harboring PLN R9C because PLN R9C is not phosphorylated and suppresses the phosphorylation of PLN wt in a dominant fashion. Thus, myocyte Ca 2ϩ reuptake will always be slow in PLN ϩ/ϩ ϩTgPLN R9C hearts ( Figure 7B ). In unstimulated PLN Ϫ/Ϫ ϩTgPLN R9C hearts, Ca 2ϩ reuptake rates are faster, lying midway between wild-type and PLN Ϫ/Ϫ rates (Figure 3 ), and they are not stimulated by isoproterenol ( Figure 6 ). These abnormalities in Ca 2ϩ uptake lead to dilated cardiomyopathy ( Figure 7C ). In a hypothetical scenario, intracellular Ca 2ϩ sensors such as calmodulin would detect abnormalities of cytosolic Ca 2ϩ and subsequently activate target proteins, including the calcium/calmodulin-dependent protein kinase, the myosin light-chain kinase, the protein kinase C, and the phosphatase calcineurin. These enzymes control classic downstream remodeling pathways that, on long-term stimulation, can produce phenotypic features of DCM and heart failure, as observed in PLN Ϫ/Ϫ ϩTgPLN R9C mice.
Murine PLN-null hearts (PLN Ϫ/Ϫ ) cannot regulate Ca 2ϩ uptake rates but nevertheless do not display overt heart failure and are even hypercontractile as a result of enhanced SR Ca 2ϩ transport. Given the related Ca 2ϩ kinetics of PLN Ϫ/Ϫ and PLN Ϫ/Ϫ ϩTgPLN R9C mice ( Figure 3A) , similar phenotypes would be expected for mice with either genotype. The fact that they are not identical suggests that PLN R9C adds a dimension of abnormal regulation that we do not yet fully understand. This type of regulation might be linked to problems that occur in humans with nonfunctional PLN. In 2 large human families, a heterozygous PLN 39stop/ϩ mutation produced a truncated and unstable protein and showed no SERCA2a inhibition in transfected HEK293 cells or adult rat cardiomyocytes. 14 One third of the older family members bearing this loss-of-function mutation developed left ventricular hypertrophy, and the inheritance of 2 mutant copies led to DCM and heart failure in 2 teenage siblings.
Conclusions
We have shown that the rate of diastolic Ca 2ϩ kinetics, as determined by the ratio of SERCA2a to PLN activity, is a crucial feature in the maintenance of a healthy heart. However, chronic alterations of PLN function can also foster the development of heart failure at high Ca 2ϩ transport rates. According to our current understanding, heart failure patients may benefit from strategies that enhance SR Ca 2ϩ uptake. Nevertheless, mere inactivation of PLN to achieve this goal may be a double-edged sword because complete lack of SERCA2a regulation might eventually promote cardiac failure. Our model proposes that therapeutic concepts aimed at myocyte Ca 2ϩ kinetics also need to restore the capability of the myocardium to regulate the speed of SR Ca 2ϩ uptakeboth up and down-as is accomplished by a properly functioning PLN that is responsive to phosphorylation. Inhibition of the Ca 2ϩ ATPase SERCA2a by PLN reduces SR Ca 2ϩ uptake (left). Inhibition is released by phosphorylation of PLN (right). B, PLN R9C inhibits phosphorylation of both mutant and wild-type PLN; as a result, PLN is constitutively active, leading to slow SR Ca 2ϩ uptake, a loss of PLN regulation, and heart failure. C, Hearts expressing PLN R9C but no PLN wt show higher Ca 2ϩ uptake rates than in A and B but still lack the potential to regulate the inhibitory effect of PLN and proceed to late-onset heart failure.
